• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Almac Group Announces Support of Agios' PYRUKYND®

Article

Almac Group confirms it has supported Agios Pharmaceuticals, Inc., in the clinical trial and commercial launch of PYRUKYND® (mitapivat).

The treatment is the first FDA approved, disease-modifying therapy for adults with hemolytic anemia caused by PK deficiency, a rare, debilitating, and lifelong form of anemia.

Read more about the work between Almac Group and Agios here.

Recent Videos
Related Content
FDA Approves Fasenra for Eosinophilic Granulomatosis with Polyangiitis

FDA Approves Fasenra for Eosinophilic Granulomatosis with Polyangiitis

Don Tracy, Associate Editor
September 18th 2024
Article

Approval was based on results from the MANDARA Phase III trial, which demonstrated the superiority of Fansenra over Nucala in patients with eosinophilic granulomatosis with polyangiitis.

Beyond the Birthrate: The Societal Costs of Maternal Mortality

Beyond the Birthrate: The Societal Costs of Maternal Mortality

Miranda Schmalfuhs
September 6th 2024
Podcast

Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.

Keytruda Demonstrates Superior Overall Survival vs. Yervoy in Advanced Melanoma

Keytruda Demonstrates Superior Overall Survival vs. Yervoy in Advanced Melanoma

Don Tracy, Associate Editor
September 18th 2024
Article

Ten-year data from the Phase III KEYNOTE-006 trial found that Keytruda produced a 34% ten-year overall survival rate compared to 23.6% for ipilimumab in patients with advanced melanoma.

Empty Shelves, Urgent Solutions

Empty Shelves, Urgent Solutions

Miranda Schmalfuhs
August 5th 2024
Podcast

Michael Abrams, Managing Partner at Numerof & Associates discusses pharmacy deserts, alternative solutions to ensure continued access to medications for all Americans, potential long term consequences if these pharmacy closures continue, and more

Braftovi Plus Mektovi Demonstrates Sustained Efficiency in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

Braftovi Plus Mektovi Demonstrates Sustained Efficiency in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

Don Tracy, Associate Editor
September 18th 2024
Article

Results from the Phase II PHAROS trial found that treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer administered Braftovi in combination with Mektovi achieved an objective response rate of 75%.

Brooke Shields

GSK Launches Brooke Shields’ Led Campaign Promoting Shingles Vaccine

Mike Hollan
September 18th 2024
Article

The campaign is based on a messaging promoting an embrace of aging.